|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 6. | Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology |
| |
J Hepatol. 2021 Jul 29;S0168-8278(21)01948-6. doi: 10.1016/j.jhep.2021.07.018.Online ahead of print.
Gennaro D'Amico 1, Luigi Maruzzelli 2, Aldo Airoldi 3, Ioannis Petridis 4, Giulia Tosetti 5, Antonio Rampoldi 6, Mario D'Amico 7, Roberto Miraglia 2, Stella De Nicola 3, Vincenzo La Mura 8, Marco Solcia 6, Riccardo Volpes 4, Giovanni Perricone 3, Cristiano Sgrazzutti 9, Angelo Vanzulli 9, Massimo Primignani 5, Angelo Luca 2, Giuseppe Malizia 10, Alessandro Federico 11, Marcello Dallio 11, Angelo Andriulli 12, Angelo Iacobellis 12, Luigi Addario 13, Matteo Garcovich 14, Antonio Gasbarrini 14, Luchino Chessa 15, Francesco Salerno 16, Giulia Gobbo 16, Manuela Merli 17, Lorenzo Ridola 18, Gianluca Svegliati Baroni 19, Giuseppe Tarantino 19, Nicola Caporaso 20, Filomena Morisco 20, Pietro Pozzoni 21, Agostino Colli 21, Luca Saverio Belli 3
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 11. | FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption |
| |
Cell Metab. 2021 Aug 3;33(8):1671-1684.e4. doi: 10.1016/j.cmet.2021.06.012. Epub 2021 Jul 15.
Bethan L Clifford 1, Leslie R Sedgeman 1, Kevin J Williams 2, Pauline Morand 3, Angela Cheng 3, Kelsey E Jarrett 1, Alvin P Chan 1, Madelaine C Brearley-Sholto 1, Annika Wahlström 4, Julianne W Ashby 1, William Barshop 3, James Wohlschlegel 3, Anna C Calkin 5, Yingying Liu 6, Anders Thorell 7, Peter J Meikle 8, Brian G Drew 9, Julia J Mack 10, Hanns-Ulrich Marschall 4, Elizabeth J Tarling 11, Peter A Edwards 12, Thomas Q de Aguiar Vallim 13
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 18. | The relationship between frailty and cirrhosis etiology: From the Functional Assessment in Liver Transplantation (FrAILT) Study |
| |
Liver Int. 2021 Jul 5.doi: 10.1111/liv.15006. Online ahead of print.
Chelsea Q Xu 1, Yara Mohamad 1, Matthew R Kappus 2, Brian Boyarsky 3, Daniel R Ganger 4, Michael L Volk 5, Robert S Rahimi 6, Andres Duarte-Rojo 7, Mara McAdams-DeMarco 3 8, Dorry L Segev 3 8, Daniela P Ladner 9 10, Elizabeth C Verna 11, Joshua Grab 12, Monica Tincopa 13, Michael A Dunn 7, Jennifer C Lai 1
|
|
| |
|
|
| |
| 20. | Three Different Genetic Risk Scores Based on Fatty Liver Index, Magnetic Resonance Imaging and Lipidomic for a Nutrigenetic Personalized Management of NAFLD: The Fatty Liver in Obesity Study |
| |
Diagnostics (Basel). 2021 Jun 13;11(6):1083. doi: 10.3390/diagnostics11061083.
Nuria Perez-Diaz-Del-Campo 1 2, Jose I Riezu-Boj 2 3, Bertha Araceli Marin-Alejandre 1 2, J Ignacio Monreal 3 4, Mariana Elorz 3 5, José Ignacio Herrero 3 6 7, Alberto Benito-Boillos 3 5, Fermín I Milagro 1 2 3 8, Josep A Tur 8 9, Itziar Abete 1 2 3 8, M Angeles Zulet 1 2 3 8, J Alfredo Martinez 1 2 3 8
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 25. | TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled Ph2a trial |
| |
Gastroenterology. 2021 Jul 20;S0016-5085(21)03276-5. doi: 10.1053/j.gastro.2021.07.025.Online ahead of print.
Rohit Loomba 1, Rizwana Mohseni 2, K Jean Lucas 3, Julio A Gutierrez 4, Robert G Perry 5, James F Trotter 6, Robert S Rahimi 6, Stephen A Harrison 7, Veeral Ajmera 8, Jeffrey D Wayne 9, Marie O'Farrell 10, William McCulloch 10, Katharine Grimmer 10, Mary Rinella 11, Vincent Wai-Sun Wong 12, Vlad Ratziu 13, Gregory J Gores 14, Brent A Neuschwander-Tetri 15, George Kemble 10
|
|
| |
|
